

Nicole A Shonka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6311066/publications.pdf>

Version: 2024-02-01

42
papers

908
citations

840776

11
h-index

477307

29
g-index

44
all docs

44
docs citations

44
times ranked

1960
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluating survival in subjects with astrocytic brain tumors by dynamic susceptibility-weighted perfusion MR imaging. PLoS ONE, 2021, 16, e0244275.	2.5	0
2	Differential gene expression-based connectivity mapping identified novel drug candidate and improved Temozolomide efficacy for Glioblastoma. Journal of Experimental and Clinical Cancer Research, 2021, 40, 335.	8.6	8
3	Efficacy of sequential radiation and chemotherapy in treating glioblastoma with poor performance status. Journal of Neuro-Oncology, 2020, 147, 91-95.	2.9	1
4	Primary clear cell sarcoma in the lung apex with spinal metastasis: a fatal outcome. BMJ Case Reports, 2020, 13, e231556.	0.5	2
5	Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma.. Journal of Clinical Oncology, 2020, 38, 3615-3615.	1.6	8
6	Clinical efficacy of ONC201 in thalamic H3 K27M-mutant glioma.. Journal of Clinical Oncology, 2020, 38, 3617-3617.	1.6	2
7	HGG-18. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA. Neuro-Oncology, 2020, 22, iii347-iii347.	1.2	2
8	CTNI-37. EFFICACY OF ONC201 IN PATIENTS WITH ONC201 FOR RECURRENT H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA. Neuro-Oncology, 2020, 22, ii50-ii51.	1.2	1
9	CTNI-17. CLINICAL EFFICACY AND PREDICTIVE BIOMARKERS OF ONC201 IN H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA. Neuro-Oncology, 2020, 22, ii45-ii46.	1.2	0
10	Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. Journal of Neuro-Oncology, 2019, 145, 97-105.	2.9	125
11	Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells. Journal of Experimental and Clinical Cancer Research, 2019, 38, 266.	8.6	81
12	Seizure prevalence, contributing factors, and prognostic factors in patients with leptomeningeal disease. Journal of the Neurological Sciences, 2019, 403, 19-23.	0.6	8
13	Highly Aggressive and Radiation-Resistant, "Atypical" and Silent Pituitary Corticotrophic Carcinoma: A Case Report and Review of the Literature. Case Reports in Oncology, 2019, 12, 139-146.	0.7	4
14	Evaluating the decisions of glioma patients regarding clinical trial participation: a retrospective single provider review. Medical Oncology, 2019, 36, 34.	2.5	6
15	Post-operative perfusion and diffusion MR imaging and tumor progression in high-grade gliomas. PLoS ONE, 2019, 14, e0213905.	2.5	15
16	ACTR-34. SINGLE AGENT ONC201 IN PREVIOUSLY-TREATED, PROGRESSIVE ADULT H3 K27M-MUTANT GLIOMA. Neuro-Oncology, 2019, 21, vi20-vi21.	1.2	1
17	PDCT-12. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA. Neuro-Oncology, 2019, 21, vi186-vi186.	1.2	2
18	Novel therapies hijack the blood-brain barrier to eradicate glioblastoma cancer stem cells. Carcinogenesis, 2019, 40, 2-14.	2.8	12

#	ARTICLE	IF	CITATIONS
19	Single agent ONC201 in adult recurrent H3 K27M-mutant glioma.. Journal of Clinical Oncology, 2019, 37, 3005-3005.	1.6	3
20	Safety of long-term anticoagulation in patients with brain metastases. Medical Oncology, 2018, 35, 43.	2.5	9
21	NCMP-25. SEIZURE INCIDENCE AND CONTRIBUTING FACTORS IN PATIENTS WITH LEPTOMENINGEAL DISEASE. Neuro-Oncology, 2018, 20, vi199-vi199.	1.2	0
22	ACTR-34. INTEGRATED CLINICAL EXPERIENCE WITH ONC201 IN PREVIOUSLY-TREATED H3 K27M-MUTANT GLIOMA PATIENTS. Neuro-Oncology, 2018, 20, vi19-vi19.	1.2	3
23	INNV-46. EVALUATING THE DECISIONS OF GLIOMA PATIENTS REGARDING CLINICAL TRIAL PARTICIPATION, A RETROSPECTIVE SINGLE PROVIDER STUDY. Neuro-Oncology, 2018, 20, vi147-vi147.	1.2	0
24	Natural products: a hope for glioblastoma patients. Oncotarget, 2018, 9, 22194-22219.	1.8	77
25	Integrated clinical experience with ONC201 in H3 K27M glioma.. Journal of Clinical Oncology, 2018, 36, 2059-2059.	1.6	1
26	Targeted Treatment of Brain Metastases. Current Neurology and Neuroscience Reports, 2017, 17, 37.	4.2	28
27	Searching for Synergy: Combining Drugs and Stereotactic Radiosurgery for the Treatment of Brain Metastases. Journal of Oncology Practice, 2016, 12, 713-714.	2.5	0
28	EGFR monoclonal antibodies in locally advanced head and neck squamous cell carcinoma: What is their current role?. Critical Reviews in Oncology/Hematology, 2016, 99, 170-179.	4.4	18
29	Complications of anticoagulant therapy in patients with brain metastases.. Journal of Clinical Oncology, 2016, 34, 2078-2078.	1.6	1
30	Biomarkers for glioblastoma: MMP2 and NGAL.. Journal of Clinical Oncology, 2016, 34, e13516-e13516.	1.6	6
31	Undifferentiated Embryonal Sarcoma of Liver. Rare Tumors, 2015, 7, 130-132.	0.6	10
32	PC or PCV, That Is the Question: Primary Anaplastic Oligodendroglial Tumors Treated with Procarbazine and CCNU With and Without Vincristine. Anticancer Research, 2015, 35, 5467-72.	1.1	10
33	IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro-Oncology, 2014, 16, 81-91.	1.2	370
34	Intrathecal Interleukin-2 for Melanomatous Meningitis. Journal of Clinical Oncology, 2014, 32, e111-e113.	1.6	8
35	Near Misdiagnosis of Glioblastoma as Primary Central Nervous System Lymphoma. Journal of Clinical Medicine Research, 2014, 6, 299-301.	1.2	3
36	PC or PCV? That is the question: A retrospective review of primary anaplastic oligodendroglial tumors treated with procarbazine and CCNU without or with vincristine.. Journal of Clinical Oncology, 2014, 32, 2046-2046.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: a retrospective review within the era of temozolomide. <i>Journal of Neuro-Oncology</i> , 2013, 113, 305-311.	2.9	24
38	Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept. <i>Targeted Oncology</i> , 2013, 8, 117-125.	3.6	10
39	Adult medulloblastoma, from spongioblastoma cerebelli to the present day: a review of treatment and the integration of molecular markers. <i>Oncology</i> , 2012, 26, 1083-91.	0.5	4
40	Targets for therapy in ependymoma. <i>Targeted Oncology</i> , 2011, 6, 163-169.	3.6	11
41	Atypical Teratoid/Rhabdoid Tumors in Adults: A Case Report and Treatment-Focused Review. <i>Journal of Clinical Medicine Research</i> , 2011, 3, 85-92.	1.2	33
42	High-Dose Therapy (HDT) with Hematopoietic Stem Cell Transplantation (HSCT) Is Effective Therapy for Patients with Non-Hodgkin Lymphoma (NHL) and Central Nervous System (CNS) Involvement. <i>Blood</i> , 2010, 116, 1358-1358.	1.4	1